top of page

TRANSACTIONS

Fairmount Partners has closed 300+ domestic and international transactions since inception throughout North and South America, Asia, Australia, Europe and the Middle East

Bridge Pharmaceuticals acquired by AVANZA Laboratories

  • Fairmount Partners
  • Dec 23, 2009
  • 1 min read

GAITHERSBURG, MD – December 23, 2009 – Today AVANZA Laboratories LLC announced its acquisition of the US operations of Bridge Pharmaceuticals, Inc., an international provider of drug research and development services, in a management buyout.


AVANZA’s management team and scientific staff have a well-established reputation providing GLP drug development services to pharmaceutical, biotech, and government organizations for over sixteen years. These services include general toxicology, safety pharmacology, and developmental and reproductive studies along with supporting chemistry. AVANZA will continue to offer the high level of client focused quality service and study execution with plans on expanding its Program Management and Regulatory Consulting capabilities.


Carlos Orantes, President and CEO of AVANZA and formerly Vice President and General Manager of Bridge’s Maryland Laboratory, commented: “This is a very exciting day for all of us at AVANZA. We are focused on continuing to deliver the service and scientific excellence that our clients have grown to expect.” The management team of AVANZA Laboratories is supported by a senior scientific team formerly with Bridge’s Maryland Laboratory with extensive industry experience. Additional information about AVANZA Laboratories can be found at www.avanzalaboratories.com.


Bridge Pharmaceuticals, Inc. was represented by Fairmount Partners, a leading investment bank serving life science. Fairmount assisted the owners in arranging and closing the transaction. Neal McCarthy, Managing Director of Fairmount Partners commented, “It was a great pleasure working with Bridge, and we are confident that Carlos and his management team at the Maryland lab will be successful in driving future growth in the preclinical toxicology field.”


Principals of Fairmount Partners acted as advisors to Bridge Pharmaceuticals in this transaction.


Contact

Neal McCarthy

Managing Director, Fairmount Partners

bottom of page